March 11, 2021 New Modalities and Biopharma Partnerships
At Rentschler Biopharma, we support our clients with new modalities and innovative services, as well as optimal processes for biopharmaceutical development and manufacturing. These aspects have been elaborated on in two insightful interviews in the latest issue of the European Biotechnology Magazine of the ©BIOCOM AG.
Our Senior VP Global Business Development, Federico Pollano speaks in the first interview about how supporting both German mRNA-based COVID-19 vaccine developers BioNTech SE and CureVac N.V., our company has expanded into the promising field of RNA manufacturing. Furthermore, he touches upon our recent expansion into the cell and gene therapy market.
In the second interview, Dr Birgit Ehrenberg, Process Manager, and Monika Haeußler, Quality Control (QC) Manager share insights into their latest projects. They are among our innovators that continuously develop new processes for biopharmaceutical production to tackle life-threatening diseases. They share how close collaboration with chromatography experts from Tosoh Bioscience helped them develop robust, scalable, and economically viable downstream processes and reliable bioanalytical methods. For more details click here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication